# Inotrem

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inotrem

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.inotrem.com
- Total disclosed funding: $38M
- Latest round: Series B (Apr 4, 2020)
- Investors on record: 7

## About

Based in France, Inotrem SA is a biotechnology company focused on developing innovative immunotherapy solutions that target the TREM-1 pathway to manage inflammatory responses in critical healthcare settings.Inotrem SA, founded in 2013 and headquartered in Paris, France, specializes in immunotherapy aimed at treating severe inflammatory diseases. The company has engaged in six deals and recently completed a Series B funding round in January 2023, raising a total of EUR 17.000 mn. The CEO is Sven Zimmermann.Inotrem specializes in developing immunotherapy solutions that focus on the TREM-1 pathway, crucial for managing inflammatory responses. Its lead product, nangibotide, is in late-stage clinical development for acute inflammatory diseases like septic shock and COVID-19. Additionally, Inotrem is advancing anti-TREM monoclonal antibodies to address chronic inflammatory diseases, primarily targeting healthcare providers and institutions in the U.S. and Europe.Inotrem reported revenue of EUR 185.9 mn for the year 2019. The company's revenue model relies on partnerships and collaborations with healthcare institutions, focusing on the commercialization of nangibotide and facilitating access to innovative treatments for critical medical needs.In January 2023, Inotrem SA secured funding from the Crohn's & Colitis Foundation to support the development of INO-02, a long-acting therapeutic aimed at modulating the TREM-1 pathway. The company plans to further expand its market presence in the U.S. and Europe with its innovative treatments and anticipates launching INO-02 in the coming years.

## Funding rounds

- Series B, Apr 4, 2020, $3.2M — Fountain Healthcare Partners
- Series B, Sep 27, 2019, $26M — Sofinnova Partners, Andera Partners, BioMed Partners, Invus [DUP], 5Y Capital, Inserm Transfert Initiative
- Series A, Mar 31, 2014, $8.9M — Sofinnova Partners, Andera Partners, BioMed Partners, Inserm Transfert Initiative

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series A, Series B
- Invus [DUP] — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series B